Anaphore snares $115M development pact; Bayer invests €35M in new biologics facility; Two biotechs ready IPOs;

 @FierceBiotech: Biotech Calendar: FDA Drug Approvals in 2011. (by Adam Feuerstein) Story | Follow @FierceBiotech

 @JohnCFierce: Amgen and Actelion CEOs got chummy last week, but no formal buyout offer was extended. News | Follow @JohnCFierce

> San Diego-based Anaphore says that it will pocket a $5 million upfront fee and up to $110 million in milestones after inking an R&D pact with Mitsubishi Tanabe Pharma covering the development of novel protein therapies for autoimmune diseases. "This agreement exemplifies Anaphore's plan to form partnerships while exploring the potential of Atrimers to improve therapy in a wide range of diseases," said Katherine Bowdish, Ph.D., Anaphore's CEO. Anaphore release

> Bayer is investing €35 million into a new facility to produce experimental biologics for its clinical trials. Bayer release

> Two biotechs, BG Medicine and Ventrus Biosciences, are planning to go public this week. Report

> PPD says it will invest $28 million to expand its Lab Services Division in Virginia over the next three years. Article

> ReNeuron says that it plans to raise £10 million from investors. Story

And Finally... Officials in Oregon crunched the numbers on the state's bioscience industry and concluded that biotech contributes more than $4 billion a year to the local economy. That's an 18 percent increase from just two years ago. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.